Related Experiment Video
Updated: Feb 14, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
A novel ARMS-based assay for the quantification of EGFR mutations in patients with lung adenocarcinoma
Yazhen Zhu1, Zhiwei Guo2, Ying Liu1
1Department of Pathology, Guangdong Provincial Hospital of TCM, Guangzhou University of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong 510120, P.R. China.
Abstract:
Quantification of epidermal growth factor receptor (EGFR) mutations is important for the prediction of tyrosine kinase inhibitor (TKI) efficacy in patients with non-small cell lung cancer (NSCLC). However, clinicians lack a sensitive and convenient method to quantify EGFR mutant abundance. The present study introduces a novel method, namely amplification refractory mutation system (ARMS)-Plus, for the quantitative analysis of EGFR exon 19 deletion (19Del), L858R and T790M mutations. Formalin-fixed paraffin-embedded tumor samples were collected from 77 patients with lung adenocarcinoma. DNA was extracted and analyzed for EGFR mutations using ARMS-Plus. The performance of ARMS-Plus was then compared with that of conventional ARMS-polymerase chain reaction (ARMS-PCR) and droplet digital PCR (ddPCR). The results demonstrated that the concordance rate of EGFR mutation testing between ARMS-Plus and ddPCR was 98.7% (76/77, Kappa=0.9739). 19Del and L858R mutations were detected in 23 and 12 patients, respectively. There was a significant difference between ARMS-Plus and ddPCR in the evaluation of 19Del mutant abundance (P=0.0002); however, not in that of L858R mutant abundance (P=0.7334). The ARMS-Plus results in L858R mutant abundance were concordant with that of ddPCR (R2=0.8081). These results indicated that the sensitivity and specificity of ARMS-Plus in identifying EGFR mutations were similar to that of ddPCR. For quantitative analysis, the results of ARMS-Plus in evaluating L858R mutant abundance revealed a positive correlation with the ddPCR results. Thus, ARMS-Plus provides an alternative method, which is reliable and cost-effective, to quantify EGFR mutations and thereby, aid treatment decisions in patients with lung adenocarcinoma.
Insights
A new method, amplification refractory mutation system (ARMS)-Plus, accurately quantifies epidermal growth factor receptor (EGFR) mutations in lung cancer patients. This reliable and cost-effective approach aids in predicting tyrosine kinase inhibitor efficacy.
Area of Science:
- Oncology
- Molecular Diagnostics
- Genetics
Background:
- Accurate quantification of epidermal growth factor receptor (EGFR) mutations is crucial for predicting tyrosine kinase inhibitor (TKI) efficacy in non-small cell lung cancer (NSCLC).
- Current methods for quantifying EGFR mutations lack sensitivity and convenience for clinical application.
- EGFR mutations, including exon 19 deletion (19Del) and L858R, are key targets for NSCLC treatment.
Purpose of the Study:
- To introduce and evaluate a novel method, amplification refractory mutation system (ARMS)-Plus, for the quantitative analysis of EGFR mutations (19Del, L858R, T790M).
- To compare the performance of ARMS-Plus with conventional ARMS-polymerase chain reaction (ARMS-PCR) and droplet digital PCR (ddPCR).
- To assess the reliability and cost-effectiveness of ARMS-Plus for clinical decision-making in lung adenocarcinoma patients.
Main Methods:
- Collected formalin-fixed paraffin-embedded tumor samples from 77 lung adenocarcinoma patients.
- Extracted DNA and analyzed EGFR mutations using the novel ARMS-Plus method.
- Compared ARMS-Plus results with conventional ARMS-PCR and droplet digital PCR (ddPCR) for concordance and quantitative accuracy.
Main Results:
- ARMS-Plus demonstrated a high concordance rate (98.7%) with ddPCR for EGFR mutation testing.
- Sensitivity and specificity of ARMS-Plus were found to be similar to ddPCR.
- ARMS-Plus showed a positive correlation with ddPCR in quantifying L858R mutant abundance, indicating reliable quantitative analysis.
Conclusions:
- ARMS-Plus is a sensitive, specific, and reliable method for quantifying EGFR mutations in lung adenocarcinoma.
- This novel technique offers a cost-effective alternative for EGFR mutation analysis, supporting personalized treatment strategies.
- ARMS-Plus can aid clinicians in making informed treatment decisions for NSCLC patients based on EGFR mutation status.
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Viral Mutations
Muscles that Move the Arm
The pectoralis major has two origins. Its clavicular head originates on the medial half of the clavicle. In contrast, the sternocostal head originates on the costal cartilages of ribs 1-6, the sternum, and the aponeurosis of the external oblique of the...
Lung Capacity
Mutation, Gene Flow, and Genetic Drift

